This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

InVentiv Clinical Solutions Expands Its Global Alliance With Partnerships In Europe, Asia And Africa

HOUSTON, May 24, 2010 (GLOBE NEWSWIRE) -- inVentiv Clinical, a division of inVentiv Health (Nasdaq:VTIV), today announced a substantive expansion of the inVentiv Clinical Global Alliance with the additions of Protech Pharmaservices Corporation (PPC), Ecron Acunova and RDDA. These partners, along with ActivaCRO, will broaden inVentiv Clinical Solutions' clinical research capabilities in Latin America, Asia, Europe and Africa and provide CRO service coverage in more than 50 countries.

PPC ( ) is inVentiv Clinical's Asia Pacific partner with its headquarters located in Taiwan. With vast clinical experience across Asia, PPC is renowned in major countries of clinical interest such as Taiwan, Japan, China, Korea, Hong Kong, Singapore, Malaysia and Australia. PPC is dedicated to serving the pharmaceutical, biotechnology, generic drug and medical device industries with a full spectrum of drug development solutions, including phase I - IV clinical study management, bioavailability / bioequivalence studies, central laboratory, data management and statistical analysis.

Ecron Acunova ( ), inVentiv Clinical's partner for Europe, has its European headquarters in Frankfurt, Germany and operations across Europe, Asia and the Americas. With 23 years of clinical expertise, Ecron Acunova provides end-to-end services for phase I - IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab for pharmaceutical, biotech, nutritional, medical diagnostic and device sponsors. Ecron Acunova has existing relationships with several members of the Global Alliance, including an ongoing collaboration with Essential CRO, which was acquired by inVentiv Clinical early 2010, and a prior partnership with PPC in Taiwan.

RDDA ( ), inVentiv Clinical's African partner, is a contract research organization based in Pretoria, South Africa and was founded by three partners with a vision to provide the international pharmaceutical industry with expert services in clinical trials in Africa. RDDA provides regulatory, project management and monitoring support across Africa including South Africa, Namibia, Botswana, Zambia, Kenya, Mozambique and Zimbabwe.

"We are very pleased to welcome PPC, Ecron Acunova and RDDA to the inVentiv Clinical Global Alliance, which already includes ActivaCRO in Latin America ( ). The expansion of our alliance is consistent with our mission to help clients accelerate quality clinical research in a cost-effective manner," comments Michael Hlinak, President and CEO of inVentiv Clinical. "By forging alliances with these first-class partners, we are better positioned to provide our clients the unique, flexible solutions and unmatched quality they have come to expect from inVentiv Clinical, but on a global scale where it is needed today. Furthermore, this Global Alliance represents significant operational integration and access to rapidly developing clinical research markets."

"We are pleased to offer our delivery capabilities in Western and Eastern European countries, including Ukraine and Russia, and to the partners in the inVentiv Clinical network," said D A Prasanna, Founder and Vice Chairman of Ecron Acunova. 

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,088.36 +58.15 0.32%
S&P 500 2,091.38 +9.50 0.46%
NASDAQ 4,809.8050 +36.3330 0.76%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs